In Vivo CAR-T Data and Pipeline PlansThe company highlighted early clinical data for LB2501, a CD19/CD20 dual-targeting in vivo CAR-T therapy being studied in relapsed or refractory non-Hodgkin’s lymphoma. The program is subject to the company’s collaboration agreement with Johnson & Johnson, and management did not provide additional details. Legend said it remains interested in pursuing in vivo CAR-T opportunities in autoimmune disease across multiple potential targets. About Legend Biotech (NASDAQ:LEGN)Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.